Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 451-457

  Namiki, Mikio ^a   Ueno, Satoru ^a   Kitagawa, Yasuhide ^a   Fukagai, Takashi ^b   Akaza, Hideyuki ^c  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

adverse effects; androgen deprivation therapy; hormonal therapy; prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; GALETERONE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; HORMONE DERIVATIVE; ORTERONEL; PREDNISONE; SELECTIVE ANDROGEN RECEPTOR MODULATOR;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ASIAN; BONE DENSITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CAUCASIAN; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG EFFICACY; ENDOCRINE DISEASE; ETHNIC DIFFERENCE; FRACTURE; HEART INFARCTION; HOT FLUSH; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ISCHEMIC HEART DISEASE; JAPANESE; LIFESTYLE MODIFICATION; METABOLIC DISORDER; METABOLIC SYNDROME X; OSTEOPOROSIS; PATIENT SATISFACTION; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SUDDEN DEATH;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ASIAN CONTINENTAL ANCESTRY GROUP; COMBINED MODALITY THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAWAII; HUMANS; JAPAN; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84860871135     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.121     Document Type: Review

References (57)

1. Huggins C, Hodges C. Studies on prostate cancer.1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
2. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-181. (Pubitemid 351969301)
3. Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonalmedication of close monitoring. Psychooncology 2002; 11: 401-414.
4. Grant JD, Litwin MS, Lee SP, Steinberg ML, King CR. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study. J Urol 2011; 185: 1674-1680.
5. Cancer Registration Committee of the Japanese Urological Association Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005; 12: 46-61.
6. Maeda O. Option and indication for early stage prostate cancer. Jap J Cancer Chemother 2003; 30: 26-31. Japanese.
7. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006; 97: 1190-1193. (Pubitemid 43907319)
8. Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T et al. Efficacy of primary hormonal therapy for localized or locally advanced prostate cancer: Results of a 10-year followup. BJU Int 2006; 98: 573-579. (Pubitemid 44185879)
9. Egawa M, Misaki T, Imao T, Yokoyama O, Fuse H et al. Retrospective study on stage B prostate cancer in the Hokuriku District, Japan. Int J Urol 2004; 11: 304-309. (Pubitemid 38758146)
10. Kitagawa Y, Koshida K, Mizokami A, Komatsu K, Nakashima S et al. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int J Urol 2003; 10: 377-382. (Pubitemid 36936518)
11. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR et al. 4-year-follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0prostate cancer. Eur Urol 2000; 38: 706-13.
12. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-Term control or piossible cure of localized prostate cancer? Urology 2002; 60: 115-119. (Pubitemid 34722958)
13. Ueno S, Namiki M, Fukagai T, Ehara H, Usami M et al. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: A retrospective multicenter study. Int J Urol 2006; 13: 1494-1500. (Pubitemid 44786336)
14. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
15. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Rev 2005; 26: 361-379. (Pubitemid 40686649)
16. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95: 981-989. (Pubitemid 36896715)
17. Tanaka N, Hara H, Yamabe F, Takasugi K, KataokaK et al. Investigation on prostate rebiopsy and high-sensitivity PSA of prostate cancer patients receiving endocrine therapy. Jap J Urol 2005; 96: 196. Japanese.
18. Akakura K, Ito H, Sato N. Intermittent androgen suppression for prostate cancer. Nippon Rinsho 2000; 58 (Suppl): 289-91. Japanese.
19. Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H et al. Global update on defining and treating high-risk localizing prostate cancer with leuprolin: An Asian perspective. BJU Int 2007; 99 (Suppl): 6-9. (Pubitemid 44952820)
20. Kato T, Komiya A, Suzuki H, Imamoto T, Ueda T et al. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int J Urol 2007; 14: 416-421. (Pubitemid 46776218)
21. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomized phase III trial. Lancet 2009; 373: 301-308.
22. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
23. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ et al.Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006; 107: 1265-1272. (Pubitemid 44452775)
24. Zietman AL, Shipley WU. Androgen deprivation and radiation therapy in prostate cancer: The evolving case for combination therapy. Int J Radiat Oncol Biol Phys 1997; 37: 245-246. (Pubitemid 27138704)
25. Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NH et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997; 38: 1071-1077. (Pubitemid 27353688)
26. Bolla M, Collette L, Blank L, Warde P, Dubois JB et al. Long-Term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103-106.
27. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroceA et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292: 821-827. (Pubitemid 39079668)
28. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252. (Pubitemid 32727802)
29. Bolla M, de Reijke TM, van Tienhoven G, van Den Bergh AC, Oddens J et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-2527.
30. Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: A secondary analysis of RTOG 85-31. J Clin Oncol 2009; 27: 2137-2143.
31. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ et al.Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-2504.
32. Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2004; 59: 1352-1359. (Pubitemid 38954057)
33. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-799. (Pubitemid 29284127)
34. Messing EM, Manola J, Yao J. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479. (Pubitemid 43779173)
35. Bittner N, Merrick GS, Wallner KE, Butler WM. Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer. Oncology 2008; 22: 995-1017.
36. Dorff TB, Flaig TW, Tangen CM, Hussain MHA, Swanson GP et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 Study. J Clin Oncol 2011; 29: 2040-2045.
37. Labrie F, Luu-The V, Liu SX, Labrie C, Simard J et al. The key role of 17b-HSDs in sex steroid biology. Steroids 1997; 62: 148-158.
38. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M et al. The adrenal androgen, androstenediol, is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen recetor. Cancer Res 2004; 64: 765-771. (Pubitemid 38120921)
39. Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K et al. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-Androgen. Int J Urol 2010; 17: 337-345.
40. Akaza H, Hinotsu S, Usami M. Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-Term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009; 115: 3437-3445.
41. Suzuki H, Okihara K, Miyake H. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180: 921-927.
42. Segura B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8: 12-23.
43. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
44. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010; 375: 1437-1446.
45. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
46. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castrationresistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
47. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR et al. Phase II multicenter study of abiraterone acetate plus prednisone in patients in patients with docetaxel treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501.
48. Dreicer R, Agus DB, MacVicar GR, MacLean D, Zhang T et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant metastatic prostate cancer: A phase I/II open label study. Genitourin Cancer Symp Proc 2010; 89: Abstract 103.
49. Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P et al. Androgen receptor inactivation contributes to antitumor efficacy of 17a-hydroxylase/17, 20-lyase inhibitor 3b-hydroxy-17-(1H-benzimidazole-1-yl) androsta-5, 16-diene in prostate cancer. Mol Cancer Ther 2008; 7: 2348-2357.
50. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456. (Pubitemid 46630983)
51. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-2425. (Pubitemid 46999213)
52. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG85-01. J Clin Oncol 2009; 27: 92-99.
53. Akaza H. Future prospects for luteinizing-hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 2010; 85: 110-120.
54. Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009; 73: 1342-1346.
55. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-589.
56. Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma: Results from the Prostate Cancer Outcomes Study. Cancer 2003; 97:1653-62. (Pubitemid 36350709)
57. Namiki M, Mizokami A, Akaza H. Should patients with localized prostate cancer receive primary androgen deprivation therapy? Nat Clin Practi Urol 2009; 5: 648-649.